secukinumab high dose for Psoriasis

Phase-Based Progress Estimates
2
Effectiveness
3
Safety
Psoriasis+1 More
secukinumab high dose - Drug
Eligibility
< 18
All Sexes
What conditions do you have?
Select

Study Summary

This trial was testing a new medication for plaque psoriasis in children aged 6 to 18. 84 subjects were enrolled and most had moderate severity.

Eligible Conditions
  • Psoriasis

Treatment Effectiveness

Effectiveness Progress

2 of 3
This is further along than 85% of similar trials

Study Objectives

2 Primary · 2 Secondary · Reporting Duration: up to week 224

Week 12
Number and Percentage of Participants With IGA Mod 2011 0 or 1 Response
Number and Percentage of Participants With PASI 75 Response
Number and Percentage of Participants With PASI 90 Response
up to week 224
Secukinumab Concentration in Serum

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Trial Design

2 Treatment Groups

secukinumab high dose
1 of 2
secukinumab low dose
1 of 2
Experimental Treatment

84 Total Participants · 2 Treatment Groups

Primary Treatment: secukinumab high dose · No Placebo Group · Phase 3

secukinumab high dose
Drug
Experimental Group · 1 Intervention: secukinumab high dose · Intervention Types: Drug
secukinumab low dose
Drug
Experimental Group · 1 Intervention: secukinumab low dose · Intervention Types: Drug

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to week 224

Who is running the clinical trial?

Novartis PharmaceuticalsLead Sponsor
2,692 Previous Clinical Trials
3,522,955 Total Patients Enrolled
66 Trials studying Psoriasis
65,047 Patients Enrolled for Psoriasis

Eligibility Criteria

Age < 18 · All Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have moderate to severe plaque psoriasis, defined as a PASI score ≥ 12, and IGA mod 2011 score of ≥ 3, and BSA involvement of ≥10%, at randomization.
You are between 6 and 18 years of age at the time of randomization.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 3rd, 2021

Last Reviewed: October 2nd, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References